Portal de Periódicos da CAPES

Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?

1995; Mary Ann Liebert, Inc.; Volume: 5; Issue: 4 Linguagem: Inglês

10.1089/ard.1995.5.241

2690-7577

Arthur Μ. Krieg, Christian Stein,

RNA Interference and Gene Delivery

Antisense Research and DevelopmentVol. 5, No. 4 Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?Arthur M. Krieg and C. A. SteinArthur M. Krieg and C. A. SteinPublished Online:3 Apr 2009https://doi.org/10.1089/ard.1995.5.241AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail "Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?." , 5(4), p. 241FiguresReferencesRelatedDetailsCited bySupportive Oligonucleotide Therapy (SOT) as a Potential Treatment for Viral Infections and Lyme Disease: Preliminary Results3 November 2022 | Infectious Disease Reports, Vol. 14, No. 6Antisense oligonucleotide repress telomerase activity via manipulating alternative splicing or translationBiochemical and Biophysical Research Communications, Vol. 582Recent Advances in Oligonucleotide Therapeutics in Oncology24 March 2021 | International Journal of Molecular Sciences, Vol. 22, No. 7Simultaneous Targeting of Two Master Regulators of Apoptosis with Dual-Action PNA– and DNA–Peptide Conjugates22 June 2020 | Bioconjugate Chemistry, Vol. 31, No. 8Chemical Synthesis and Biological Application of Modified Oligonucleotides31 March 2020 | Bioconjugate Chemistry, Vol. 31, No. 5Interaction of ASOs with PC4 Is Highly Influenced by the Cellular Environment and ASO Chemistry15 May 2020 | Journal of the American Chemical SocietyNucleic acid anticancer agentsHybridization-Independent Effects22 June 2018Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides9 August 2017 | Nucleic Acids Research, Vol. 45, No. 18Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides24 July 2017 | Molecular Pharmaceutics, Vol. 14, No. 8Antisense Oligonucleotide-Mediated Target-Specific Gene Silencing24 November 2016Pleiotropic action of CpG-ODN on endothelium and macrophages attenuates angiogenesis through distinct pathways25 August 2016 | Scientific Reports, Vol. 6, No. 1Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity3 March 2016 | Nucleic Acids Research, Vol. 44, No. 8Synthetic SiRNA Delivery: Progress and ProspectsIn vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity26 October 2015 | Nature Biotechnology, Vol. 33, No. 11Antisense Oligonucleotide–Based Therapeutics13 January 2015Knockdown of αIIb by RNA degradation by delivering deoxyoligonucleotides piggybacked with control vivo-morpholinos into zebrafish thrombocytesBlood Cells, Molecules, and Diseases, Vol. 54, No. 1Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic14 October 2014 | Frontiers in Chemistry, Vol. 2Structure-based programming of lymph-node targeting in molecular vaccines16 February 2014 | Nature, Vol. 507, No. 7493Bioconjugation of siRNA for Site-specific Delivery26 April 2013Synthetic Dicer-Substrate siRNAs as Triggers of RNA Interference14 September 2012Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide ModifierMolecular Therapy - Nucleic Acids, Vol. 2Theory and limitations to gene therapyLipid Conjugated Oligonucleotides: A Useful Strategy for Delivery15 March 2012 | Bioconjugate Chemistry, Vol. 23, No. 6Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasisVaccine, Vol. 30, No. 26Evaluation of Novel Adjuvant Eimeria Profilin Complex on Intestinal Host Immune Responses Against Live E. acervulina Challenge InfectionAvian Diseases, Vol. 56, No. 2Advanced morpholino oligomers: A novel approach to antiviral therapyAntiviral Research, Vol. 94, No. 1Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapyBiomaterials, Vol. 32, No. 22Membrane Anchored Immunostimulatory Oligonucleotides for In Vivo Cell Modification and Localized Immunotherapy17 June 2011 | Angewandte Chemie, Vol. 123, No. 31Membrane Anchored Immunostimulatory Oligonucleotides for In Vivo Cell Modification and Localized Immunotherapy17 June 2011 | Angewandte Chemie International Edition, Vol. 50, No. 31Fluorescence Cross-Correlation Spectroscopy Reveals Mechanistic Insights into the Effect of 2′-O-Methyl Modified siRNAs in Living CellsBiophysical Journal, Vol. 100, No. 12Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens9 January 2014 | Expert Review of Vaccines, Vol. 10, No. 2Chemical Modification of Small Interfering RNA15 February 2011Nanomedicine, Vol. 6, No. 10The use of antisense oligonucleotides in Xenopus oocytesMethods, Vol. 51, No. 1RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic PlatformAnnual Review of Pharmacology and Toxicology, Vol. 50, No. 1Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides8 May 2009 | Molecular Pharmaceutics, Vol. 6, No. 3Brain Tumor Therapy with Antisense Oligonucleotides30 July 2009Chemical Modification of siRNAs for In Vivo Use Mark A. Behlke29 November 2008 | Oligonucleotides, Vol. 18, No. 4Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer15 April 2008 | Expert Opinion on Therapeutic Targets, Vol. 12, No. 5Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA virusesAntiviral Research, Vol. 78, No. 1Antisense Oligonucleotides and siRNA as Specific Inhibitors of Gene Expression: Mechanisms of Action and Therapeutic PotentialA Polysaccharide Carrier to Effectively Deliver Native Phosphodiester CpG DNA to Antigen-Presenting Cells27 May 2007 | Bioconjugate Chemistry, Vol. 18, No. 4Delivery of Antisense Oligonucleotides to Nuclear Telomere RNA by Use of a Complex between Polysaccharide and PolynucleotideBulletin of the Chemical Society of Japan, Vol. 80, No. 6Synthetic Nucleic Acids as Potential Therapeutic Tools for Treatment of Bladder CarcinomaEuropean Urology, Vol. 51, No. 2Progress towards in Vivo Use of siRNAsMolecular Therapy, Vol. 13, No. 4Transferrin-appended β-(1→3)-D-glucan schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptakee-Journal of Surface Science and Nanotechnology, Vol. 3Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA22 April 2005 | Expert Opinion on Drug Delivery, Vol. 2, No. 1Ten years of antisense inhibition of brain G-protein-coupled receptor functionBrain Research Reviews, Vol. 42, No. 2Specific Inhibition of AQP1 Water Channels in Isolated Rat Intrahepatic Bile Duct Units by Small Interfering RNAsJournal of Biological Chemistry, Vol. 278, No. 8Sequence Dependence of C5-Propynyl-dU,dC-Phosphorothioate Oligonucleotide Inhibition of the Human IGF-I Receptor: mRNA, Protein, and Cell Growth Rhys D. Fogarty, Sandra C. McKean, Paul J. White, Lynne M. Atley, George A. Werther, and Christopher J. Wraight8 July 2004 | Antisense and Nucleic Acid Drug Development, Vol. 12, No. 6The Quest for an Efficacious Antiviral for Respiratory Syncytial Virus24 June 2016 | Antiviral Chemistry and Chemotherapy, Vol. 13, No. 6Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotideInternational Immunopharmacology, Vol. 2, No. 12Evaluating the Specificity of Antisense Oligonucleotide ConjugatesJournal of Biological Chemistry, Vol. 277, No. 25Development of New Radical Reactions with a Vinylsilyl Group and Their Application to the Synthesis of Branched-Chain Sugar NucleosidesMyc down-regulation induces apoptosis in M14 melanoma cells by increasing p27kip1 levelsOncogene, Vol. 20, No. 22Antisense oligonucleotides in cutaneous therapyPharmacology & Therapeutics, Vol. 90, No. 1Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases24 February 2005 | Expert Opinion on Pharmacotherapy, Vol. 2, No. 2The 3′-modified antisense oligos promote faster hydrolysis of the target RNA by RNase H than the natural counterpartTetrahedron, Vol. 57, No. 3EWS Fli-1 Antisense Nanocapsules Inhibits Ewing Sarcoma-Related Tumor in MiceBiochemical and Biophysical Research Communications, Vol. 279, No. 2Selecting optimal antisense reagentsAdvanced Drug Delivery Reviews, Vol. 44, No. 1Electroporation-mediated delivery of 3′-protected phosphodiester oligodeoxynucleotides to the skinJournal of Controlled Release, Vol. 67, No. 2-3Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed against c-myc ROBERT M. HUDZIAK, JAMES SUMMERTON, DWIGHT D. WELLER, and PATRICK L. IVERSEN30 January 2009 | Antisense and Nucleic Acid Drug Development, Vol. 10, No. 3Highly Nuclease-Resistant Phosphodiester-Type Oligodeoxynucleotides Containing 4'α- C -Aminoalkylthymidines Form Thermally Stable Duplexes with DNA and RNA. A Candidate for Potent Antisense Molecules2 March 2000 | Journal of the American Chemical Society, Vol. 122, No. 11Gene switching: Analyzing a broad range of mutations using steric block antisense oligonucleotidesA review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotidesBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, Vol. 1489, No. 1Morpholino antisense oligomers: the case for an RNase H-independent structural typeBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, Vol. 1489, No. 1Cell binding, uptake and cytosolic partition of HIV anti-gag Phosphodiester oligonucleotides 3′-linked to cholesterol derivatives in macrophagesBioorganic & Medicinal Chemistry, Vol. 7, No. 11Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translationEuropean Journal of Clinical Investigation, Vol. 29, No. 10Vascular Smooth Muscle Cell Proliferation and Regrowth after Mechanical Injury in Vitro Are. Egr-1/NGFI-A-DependentThe American Journal of Pathology, Vol. 155, No. 3Evaluation of Different Types of End-Capping Modifications on the Stability of Oligonucleotides Toward 3′- and 5′-ExonucleasesNucleosides and Nucleotides, Vol. 18, No. 9Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell cultureNucleic Acids Research, Vol. 27, No. 13Antisense Oligonucleotides with Different BackbonesJournal of Biological Chemistry, Vol. 274, No. 31Early Growth Response Factor-1 Induction by Injury Is Triggered by Release and Paracrine Activation by Fibroblast Growth Factor-2The American Journal of Pathology, Vol. 154, No. 3Effect of polyisobutylcyanoacrylate nanoparticles and Lipofectin® loaded with oligonucleotides on cell viability and PKCα neosynthesis in HepG2 cellsBiochimie, Vol. 80, No. 12Sequence Dependency of the Internalization and Distribution of Phosphorothioate Oligonucleotides in Vascular Smooth Muscle CellsBiochemical Pharmacology, Vol. 55, No. 9Nucleosides and Nucleotides. 174. Synthesis of Oligodeoxynucleotides Containing 4'- C -[2-[[ N -(2-Aminoethyl)carbamoyl]oxy]ethyl]thymidine and Their Thermal Stability and Nuclease-Resistance Properties 114 February 1998 | The Journal of Organic Chemistry, Vol. 63, No. 5Toxicity of Oligodeoxynucleotide Therapeutic AgentsCationic Polyhexylcyanoacrylate Nanoparticles as Carriers for Antisense Oligonucleotides H.-P. ZOBEL, J. KREUTER, D. WERNER, C.R. NOE, G. KÜMEL, and A. ZIMMER30 January 2009 | Antisense and Nucleic Acid Drug Development, Vol. 7, No. 5Diazepam protects against rat hippocampal neuronal cell death induced by antisense oligodeoxynucleotide to GABAA receptor γ2 subunitBrain Research, Vol. 765, No. 1Promise and Problems of Bcl-2 Antisense TherapyJNCI Journal of the National Cancer Institute, Vol. 89, No. 14Morpholino Antisense Oligomers: Design, Preparation, and Properties JAMES SUMMERTON and DWIGHT WELLER30 January 2009 | Antisense and Nucleic Acid Drug Development, Vol. 7, No. 3Morpholino and Phosphorothioate Antisense Oligomers Compared in Cell-Free and In-Cell Systems JAMES SUMMERTON, DAVID STEIN, SUNG BEN HUANG, PAULA MATTHEWS, DWIGHT WELLER, and MICHAEL PARTRIDGE30 January 2009 | Antisense and Nucleic Acid Drug Development, Vol. 7, No. 2β-Actin Messenger RNA Localization and Protein Synthesis Augment Cell Motility24 March 1997 | Journal of Cell Biology, Vol. 136, No. 6Inhibition of carrageenan-induced spinal c-Fos activation by systemically administered c-fos antisense oligodeoxynucleotides may be facilitated by local opening of the blood-spinal cord barrierJournal of Neuroscience Research, Vol. 47, No. 6RNase H-independent antisense activity of oligonucleotide N3'->P5' phosphoramidatesNucleic Acids Research, Vol. 25, No. 4Oligonucleotides and Polynucleotides as Biologically Active CompoundsIn vivo studies with antisense oligonucleotidesTrends in Pharmacological Sciences, Vol. 18, No. 1Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C- raf kinase supports an antisense mechanism of action in vivo24 December 1996 | Proceedings of the National Academy of Sciences, Vol. 93, No. 26Specific and nonspecific inhibition of transcription by DNA, PNA, and phosphorothioate promoter analog duplexesBioorganic & Medicinal Chemistry Letters, Vol. 6, No. 23The G-tetrad in antisense targetingTrends in Genetics, Vol. 12, No. 8Inhibition of human telomerase activity by peptide nucleic acidsNature Biotechnology, Vol. 14, No. 5Structures and Motifs Involved in Toll Signaling Volume 5Issue 4Jan 1995 To cite this article:Arthur M. Krieg and C. A. Stein.Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?.Antisense Research and Development.Jan 1995.241-241.http://doi.org/10.1089/ard.1995.5.241Published in Volume: 5 Issue 4: April 3, 2009PDF download